Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

808978

registered interest
date	18/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Ovarian Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the timetable is for a decision on the next round of cancer audits; and whether ovarian cancer will be included within those audits.
tabling member constituency	North East Derbyshire
tabling member printed	Lee Rowley
uin	120087
answer	answer is ministerial correction date of answer 22/12/2017 answer text <p>NHS England, the Welsh Government and the Healthcare Quality Improvement Partnership are currently recommissioning the cancer audits that sit within the National Clinical Audit and Patient Outcomes Programme portfolio and have been charged with achieving greater alignment to produce a more sustainable delivery model. Discussions will take place over the next year on potential new topics, such as ovarian cancer and any new audits will draw on data that is already available and routinely collected, wherever possible.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 22/12/2017 12:03:11 answering member 4067 label Biography information for Steve Brine
tabling member	4652 label Biography information for Lee Rowley

747622

registered interest
date	03/07/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Ovarian Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when he plans to publish the two research studies into ovarian cancer awareness which the previous Government indicated it planned to publish in the summer of 2017.
tabling member constituency	Wellingborough
tabling member printed	Mr Peter Bone
uin	2424
answer	answer is ministerial correction date of answer 06/07/2017 answer text <p>Public Health England (PHE) has published one full evaluation report on the pilot campaign and one interim report on the regional campaign for the Be Clear on Cancer ovarian cancer campaign.</p><p> </p><p>The full evaluation of the local ovarian cancer pilot campaign which ran from 14 January – 17 March 2013 it can be accessed here:</p><p><a href="https://www.gov.uk/government/publications/ovarian-cancer-awareness-campaign-local-pilots-evaluation-report" target="_blank">https://www.gov.uk/government/publications/ovarian-cancer-awareness-campaign-local-pilots-evaluation-report</a></p><p> </p><p>The interim evaluation report on the regional ovarian cancer awareness campaign, which ran from 10 February- 16 March 2014 in the North West of England it can be accessed here:</p><p><a href="http://www.ncin.org.uk/cancer_type_and_topic_specific_work/topic_specific_work/be_clear_on_cancer/" target="_blank">http://www.ncin.org.uk/cancer_type_and_topic_specific_work/topic_specific_work/be_clear_on_cancer/</a></p><p> </p><p>PHE is planning to produce a full and final evaluation report for the Be Clear on Cancer ovarian cancer awareness regional campaign by April 2018.</p><p> </p><p>The Department’s Policy Research Unit on Cancer Awareness Screening and Early Diagnosis has undertaken a qualitative research study in which members of the public were given access to available leaflets on ovarian cancer awareness and then participated in six focus groups and interviews on their acceptability and how they would be received and understood if included within the clear screening results letter from the breast or cervical screening programme.</p><p> </p><p>This study is now complete and has been presented at the recent Cancer Research UK Early Diagnosis conference. The work is currently being written up for submission to a peer-reviewed medical journal. The Health Research Authority approval for a further qualitative research study with professionals has now been granted, and the work is in progress.</p><p> </p><p>A second project is a synthesis of published incidence, mortality, stage distribution and stage-specific survival rates for ovarian cancer by age. The aim of this project was to identify which age group would be most likely to benefit from such an intervention, in terms of risk of ovarian cancer, and room for improvement in stage at diagnosis. This study is now also complete, fully written up, and has been submitted to a journal for publication. The journal’s response is awaited.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 06/07/2017 14:52:45 answering member 4067 label Biography information for Steve Brine
tabling member	1581 label Biography information for Mr Peter Bone

705621

registered interest
date	27/02/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Ovarian Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when NHS England plans to publish its service specification on ovarian cancer.
tabling member constituency	Wellingborough
tabling member printed	Mr Peter Bone
uin	65673
answer	answer is ministerial correction date of answer 02/03/2017 answer text <p>In order for NHS England to formally consider a new or revised service specification, a number of associated reports and processes need to be completed. The Complex Gynaecological Services Clinical Reference Group (CRG) did start the process of developing a new service specification for ovarian cancer, however, this did not progress through the process. This was due to technical difficulties encountered during the Impact Assessment stage and included issues in identifying activity and the associated financial impact.</p><p> </p><p>In the subsequent period, CRGs have been restructured and the responsibility for this clinical area now resides with the Specialised Cancer Surgery CRG, within the National Cancer Programme of Care. In addition, NHS England has also published a revised process for service specification development (titled: ‘Methods’), which can be found at:</p><p><a href="https://www.england.nhs.uk/commissioning/spec-services/key-docs/" target="_blank">https://www.england.nhs.uk/commissioning/spec-services/key-docs/</a></p><p> </p><p>The Methods sets out the process for completing service specification work and, in accordance with this process, the Specialised Cancer Surgery CRG has been asked to consider progressing this work. The CRG Chair is due to discuss the matter with a representative of the Gynaecology CRG later this week and, following this, it is expected that the first step of the process will be completed by the middle of March 2017.</p> answering member constituency Warrington South answering member printed David Mowat question first answered 02/03/2017 11:10:35 answering member 4080 label Biography information for David Mowat
tabling member	1581 label Biography information for Mr Peter Bone

687043

registered interest
date	08/02/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Ovarian Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when he plans to publish the ovarian cancer-specific service specification submitted for approval by the Complex Gynaecological Services Clinical Reference Group in 2015.
tabling member constituency	Lancaster and Fleetwood
tabling member printed	Cat Smith
uin	63653
answer	answer is ministerial correction date of answer 20/02/2017 answer text <p>In order for NHS England to formally consider a new or revised service specification, a number of associated reports and processes need to be completed. The Complex Gynaecological Services Clinical Reference Group (CRG) did start the process of developing a new service specification for ovarian cancer, however, it did not complete the process. The CRG encountered technical difficulties during the Impact Assessment stage including issues identifying activity and the associated financial impact.</p><p> </p><p>In the subsequent period, CRGs have been restructured and the responsibility for this clinical area now resides with the Specialised Cancer Surgery CRG, within the National Cancer Programme of Care. In addition, NHS England has also published a revised process for service specification development (titled: ‘Methods’), which can be found at:</p><p><a href="https://www.england.nhs.uk/commissioning/spec-services/key-docs/" target="_blank">https://www.england.nhs.uk/commissioning/spec-services/key-docs/</a></p><p> </p><p>The Methods sets out the process for completing service specification work and, in accordance with this process, the Specialised Cancer Surgery CRG has been asked to consider progressing this work. It is expected that the first step of the process will be completed by the end of February 2017.</p> answering member constituency Warrington South answering member printed David Mowat question first answered 20/02/2017 15:40:53 answering member 4080 label Biography information for David Mowat
tabling member	4436 label Biography information for Cat Smith

679728

registered interest
date	27/01/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Ovarian Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when the findings of the ovarian cancer regional pilot that took place in 2014 will be published.
tabling member constituency	Washington and Sunderland West
tabling member printed	Mrs Sharon Hodgson
uin	62053
answer	answer is ministerial correction date of answer 06/02/2017 answer text <p>Public Health England has been commissioned by the Department to evaluate the Be Clear on Cancer (BCoC) Campaigns. An interim evaluation report on the ovarian cancer pilot has been published and is available on our BCoC website:</p><p><a href="http://www.ncin.org.uk/cancer_type_and_topic_specific_work/topic_specific_work/be_clear_on_cancer/" target="_blank">http://www.ncin.org.uk/cancer_type_and_topic_specific_work/topic_specific_work/be_clear_on_cancer/</a></p><p> </p><p>This includes results for public awareness and knowledge, urgent general practice (GP) referrals for suspected cancer, cancer diagnoses resulting from an urgent GP referral for suspected cancer, conversion rate, cancer diagnoses recorded in the cancer waiting times database and detection rate.</p> answering member constituency Warrington South answering member printed David Mowat question first answered 06/02/2017 13:49:17 answering member 4080 label Biography information for David Mowat
tabling member	1521 label Biography information for Mrs Sharon Hodgson

520803

registered interest
date	23/05/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Ovarian Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if his Department will take steps to ensure that the proposals to more closely align the approval process for the new cancer drugs fund with the National Institute for Health and Care Excellence do not limit access to potential life-saving treatments such as Avastin for the treatment of ovarian cancer.
tabling member constituency	Barnsley Central
tabling member printed	Dan Jarvis
uin	37866
answer	answer is ministerial correction date of answer 26/05/2016 answer text <p>Since October 2010, the Cancer Drugs Fund (CDF) has helped over 84,000 people in England in accessing life-extending cancer drugs that would not otherwise have been available to them.</p><p> </p><p>NHS England is responsible for the operational management of the Fund and has consulted, jointly with the National Institute for Health and Care Excellence, on new arrangements for the CDF which will go live on 1 July 2016.</p><p> </p><p>NHS England has advised that, under these new arrangements, it envisages that a greater number of cancer drugs will be funded from baseline commissioning. This will be as a consequence of more appropriate pricing arrangements proposed by pharmaceutical manufacturers and better evidence being available through the Fund as to longer term patient outcomes.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 26/05/2016 13:49:23 answering member 4020 label Biography information for George Freeman
tabling member	4243 label Biography information for Dan Jarvis

451569

registered interest
date	09/02/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Ovarian Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when the new treatment for ovarian cancer is likely to be available on the NHS.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	26385
answer	answer is ministerial correction date of answer 12/02/2016 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body that makes recommendations for the National Health Service on the use of selected drugs and treatments through its technology appraisal and highly specialised technologies programmes.</p><p> </p><p>In January 2016 NICE published a technology appraisal guidance recommending olaparib as an option for treating adults with relapsed, platinum sensitive ovarian, fallopian tube or peritoneal cancer who have BRCA1 or BRCA2 mutations and whose disease has responded to platinum based chemotherapy where certain criteria apply.</p><p> </p><p>NICE is currently appraising a number of other potential treatments for ovarian cancer. Further information is available at:</p><p> </p><p><a href="http://www.nice.org.uk/guidance/conditions-and-diseases/cancer/ovarian-cancer" target="_blank">www.nice.org.uk/guidance/conditions-and-diseases/cancer/ovarian-cancer</a></p><p> </p><p>In developing its technology appraisal guidance NICE works closely with stakeholders, including manufacturers. In the absence of NICE guidance, it is for commissioners to make funding decisions based on an assessment of the available evidence.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 12/02/2016 16:23:21 answering member 4020 label Biography information for George Freeman
tabling member	4131 label Biography information for Jim Shannon

437935

registered interest
date	14/12/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Ovarian Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what guidance his Department has issued to (a) clinical commissioning groups, (b) hospital trusts and (c) health and well-being boards on BRCA gene testing for (i) patients who have been diagnosed with ovarian cancer and (ii) people identified as likely to have the BRCA gene mutation due to their family history.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	19874
answer	answer is ministerial correction date of answer 17/12/2015 answer text <p>NHS England published a new Clinical Commissioning Policy on Genetic Testing for BRCA1/2 mutations in July 2015, based on updated guidelines issued by the National Institute for Health and Care Excellence. This policy applies to patients diagnosed with ovarian cancer and people likely to have the BRCA gene mutation due to their family history.</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 17/12/2015 14:17:23 answering member 3918 label Biography information for Jane Ellison
tabling member	1533 label Biography information for Dame Diana Johnson

386682

registered interest
date	30/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Ovarian Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he is taking to reduce the incidence of ovarian cancer; and if he will introduce screening for that cancer for women aged over 50.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	4868
answer	answer is ministerial correction date of answer 08/07/2015 answer text <p>The UK National Screening Committee (UK NSC) does not currently recommend screening for ovarian cancer except in the context of the Medical Research Council’s UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). The UK NSC will review the evidence for ovarian cancer screening against its internationally recognised criteria following publication of the UKCTOCS results which are currently expected in early 2016.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 08/07/2015 13:45:06 answering member 3918 label Biography information for Jane Ellison
tabling member	4131 label Biography information for Jim Shannon

178159

registered interest
date	05/02/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Ovarian Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the effect of the Be Clear on Cancer regional pilot in ovarian cancer on (a) survival rates, (b) early diagnosis and (c) general awareness of ovarian cancer.
tabling member constituency	Pudsey
tabling member printed	Stuart Andrew
uin	223596
answer	answer is ministerial correction date of answer 10/02/2015 answer text <p>For each Be Clear on Cancer campaign there is a comprehensive evaluation process. Data is collected on a number of metrics to reflect the possible campaign impact on key elements of the patient pathway. Metrics evaluated include survival rates, indicators for earlier diagnosis and general awareness of ovarian cancer symptoms.</p><p> </p><p> </p><p> </p><p>For the regional ovarian pilot in the North West, we have so far been able to look at the following metrics:</p><p> </p><p>- cancer awareness levels;</p><p> </p><p>- urgent general practitioner (GP) (two week wait) referrals for suspected gynaecological cancers;</p><p> </p><p>- ovarian cancers diagnosed following a two week wait referral;</p><p> </p><p>- all ovarian cancers diagnosed and recorded in the cancer waiting times database;</p><p> </p><p>- conversion rate (percentage of two week wait referrals resulting in a cancer diagnosis); and</p><p> </p><p>- detection rate (percentage of Cancer Waiting Times (CWT) recorded cancers resulting from a two week wait referral).</p><p> </p><p> </p><p> </p><p>Some of the information required to fully evaluate campaigns takes longer to collate and analyse but gradually over time, when combined together, the metrics we analyse build up a detailed picture of potential campaign effects. This will include analysis of the following data:</p><p> </p><p>- GP attendances;</p><p> </p><p>- diagnostic tests, including CA125;</p><p> </p><p>- numbers of cancers recorded by the National Cancer Registration Service;</p><p> </p><p>- stage at diagnosis; and</p><p> </p><p>- one year survival.</p><p> </p><p><strong> </strong></p><p> </p><p>The National Cancer Intelligence Network (part of Public Health England) have confirmed that they will publish a full and final evaluation report for the regional ovarian cancer pilot campaign as soon as possible, when analysis of all metrics is complete. However, in advance of a final evaluation report, they aim to publish an interim report containing the cancer awareness levels and the results from the analysis of CWT data before the end of February 2015, at which time we will share these results with the ovarian cancer expert group and ovarian cancer charities.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 10/02/2015 16:09:39 answering member 3918 label Biography information for Jane Ellison
tabling member	4032 label Biography information for Stuart Andrew